[{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ipratropium Bromide","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Inapplicable"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ipratropium Bromide","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Inapplicable"},{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ipratropium Bromide","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ipratropium Bromide","moa":"||M3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ipratropium Bromide","moa":"||M3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Bromuro de ipratropio

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Bromuro de ipratropio

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

36 API Suppliers, 9 USDMF, 9 CEP/COS, 1 JDMF, 5 EU WC, 9 KDMF, 14 NDC API, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

192 FDF Dossiers, 45 FDA Orange Book, 81 Europe, 18 Canada, 5 Australia, 23 South Africa, 20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SPRAY, METERED;NASAL - 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INHALATION - EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

5 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 2 Solubilizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 16 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions, 56 Regulatory FDF Prices

MARKET PLACE

11 APIs, 6 FDF Dossiers, 1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

5 US Patents, 1 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM, 9 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Lupin Ltd

India

EPSC

Not Confirmed

02

Lupin Ltd

India

EPSC

Not Confirmed

03

Neutec Ar-Ge San ve Tic A.?

Country

EPSC

Not Confirmed

04

Neutec Ar-Ge San ve Tic A.?

Country

EPSC

Not Confirmed

05

Neutec Ar-Ge San ve Tic A.?

Country

EPSC

Not Confirmed

06

London Health Sciences Centre

Country

EPSC

Not Confirmed

07

Viatris

U.S.A

EPSC

Not Confirmed

08

Beaumont Hospital

Country

EPSC

Not Confirmed

09

Wouter H. van Geffen

Country

EPSC

Not Confirmed

10

Boehringer Ingelheim GmbH

Germany

EPSC

Not Confirmed